Avacta Share Discussion Threads

[stockhunters] 29/2/2024 07:55

so is there a 2nd batch of 50p coming out on 4th also?

[1347] 29/2/2024 07:50

So the pipeline of Affimer based diagnostics has gone west, even after buying Launch Diagnostics they haven't got a single Affimer based test on the market, despite years and years of working on it. Now they want to sell it all less than 18 months later?! Total debacle that's left a legacy £38.25 m death spiral payday loan.

In fact what's happening to Affimers in anything? Well very little it seems, not only no tests but no therapeutics have even made it to clinical trials as far as I am aware, anyone know of any? How many years were they working on that 'disruptive technology that was going to change the world? Well since 2011 isn't it?

So all that's left is Precision, where they have one drug, that they just recycled from Dr. William Bachovchin at Arispah that so far hasn't even completed a Phase 1 trial that they started in August 2021 and which is so wonderful that not a single Big Pharma company has stepped in to finance a Phase 2 trial for.

You've been had...

[amanitaangelicus] 29/2/2024 07:18

Tom ...Nasdaq is always a cheap, expected comment. The listing reqs are quite tough, way moreso than the Aim Circus. A brief look would dispel that notion at this point in time as rather far fetched. Going fwd, who knows? Balance of probs? Unlikely.

[tomavery19] 28/2/2024 23:30

Just look at the state of Arb on nasdaq and 88e on otc they get smashedBeing listed on nasdaq is a slow death sentence

[jonnywalker77] 28/2/2024 22:49

The idea that a sub 200m market cap UK co (which this will be tmr) can get traction on NASDAQ is comical and pure copium to suck in more mug punter PI money. The best this could hope for in the US is OTC/Pink Sheets. Pathetic 65k from the board tells you this is a busted flush

[jonnywalker77] 28/2/2024 22:46

The idea that a

[amanitaangelicus] 28/2/2024 21:56

Missed the T Rex rns ...foot me!!! Pillaged. Prepare the gorilla tape - you.re gonna need it. Spit roast time for sure. Ben Dover well and truly gonna be on top form. Dont say you werent warned. TimeLord ' Shaft' Smith has left the building. How.s Myles taken the news? Myles, Myles, come off that roof!

[bbd2] 28/2/2024 21:13

A comprehensive and positive trial update and a hint of a dual Nasdaq listing will make good reading for NEW investors. I certainly wouldn’t want to be short in this one and recent longs should be fine too. But what do I know! Lol

[1347] 28/2/2024 20:51

You mean like a dead cat bounce?

[tomavery19] 28/2/2024 18:50

I may buy some purely for a bounce trade that is all no interest holding long termBut it may not bounce it could drop well below 50p first

[atmysignal] 28/2/2024 18:29

The hate and anger here is understandable But this will bounce hard

[atmysignal] 28/2/2024 18:28

Mega bounce tomorrow 13% short need to close

[bonzo] 28/2/2024 18:13

The technology IS that great...

[fieldhouse] 28/2/2024 18:07

owf,
The trials were for safety with patients that had been heavily treated with dox and were terminal.The small sample that responded was a bonus and hence the two weekly dosing.
I think you are being unduly negative and are obsessed with Arisaph withdrall

I also suspect that the fund raise was forced on the company by the US to ensure funds were in place to complete the next complete phase to the end of 2025.

Still everything to play for but confidence severely dented

Rather pi----of of, but wiser

[bspgamer] 28/2/2024 17:53

Remember silence therapeutics, used to be pence on the AIM now $25 on NASDAQ. The same is coming here, patience is a virtue

[jason29] 28/2/2024 17:51

Thankfully only have a smallish (Still painful) holding in here. I'm not convinced throwing good money after bad is the right way to go, but would be happy to be convinced otherwise? As someone mentioned, if the Technology was that great, someone would have been all over them before now. Win some and lose some I guess.

[ohwhatfun] 28/2/2024 17:51

Yes some very sobering comments

Not the holy grail, others in the same game (dox prodrug) that Avacta (assuming success) believe that they can compete with.

Hardly surprising that companies are not interested when the higher dose levels produced hardly any response rates (ORR) out of 40 patients.

It’s very poor v Dox trials, points many have raised repeatedly.

It may be why Arisaph dumped it.
It really does not look good.

[loglorry1] 28/2/2024 17:43

Hold on a moment @tickboo. Surely if you believe you should just give them more money. The lower the price the better as it allows you to accumulate more shares before the eventual monster pay day when AVA6K comes in.

It might be a bit uncomfortable but if you still have faith you should buy more cheap.

Personally I never believed Smithy but I do believe there are believers.

[wilmer100] 28/2/2024 17:37

I had very optimistic hopes for this company and its technology.Now I think it's a dog of a company. Obviously big pharma are not interested and to have to raise money at such a low price indicates to me that this is now a super high risk investment. If the management can further prove their platform technology then this could be an extremely high reward but I now have doubts.It was good to fantasize for a long while, that this could be a game changer. Nevermind.

[hamidahamida] 28/2/2024 17:25

Quarterly loan payments dilution Unbelievable

[pwhite73] 28/2/2024 17:23

When all is said and done the root cause of all of this is the failure to prove the efficacy of AVA6000. This is the sole reason it was never subject to peer review. Even the current Phase I results on patient numbers alone is insufficient to warrant the expenditure of moving it to Phase II.

If AVA6000 even remotely proved efficacy institutions and larger biotechs would be falling over themselves to take a stake in the company.

[amanitaangelicus] 28/2/2024 17:21

Tick ...at least you.re being honest ...hold...you might get back to 95p with a gd wind.